Switch theme
Sign up to access all valuation multiples
Carl Zeiss Meditec is one of the largest medical technology companies in the world, and it operates in two segments: ophthalmic devices and microsurgery. OPT, which made up 75% of sales in 2022, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.
1977
4.8K+
LTM Revenue $2.4B
LTM EBITDA $424M
$5.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Carl Zeiss Meditec has a last 12-month revenue (LTM) of $2.4B and a last 12-month EBITDA of $424M.
In the most recent fiscal year, Carl Zeiss Meditec achieved revenue of $2.3B and an EBITDA of $453M.
Carl Zeiss Meditec expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Carl Zeiss Meditec valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.4B | XXX | $2.3B | XXX | XXX | XXX |
| Gross Profit | $1.3B | XXX | $1.2B | XXX | XXX | XXX |
| Gross Margin | 53% | XXX | 53% | XXX | XXX | XXX |
| EBITDA | $424M | XXX | $453M | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 20% | XXX | XXX | XXX |
| EBIT | $288M | XXX | $198M | XXX | XXX | XXX |
| EBIT Margin | 12% | XXX | 9% | XXX | XXX | XXX |
| Net Profit | $190M | XXX | $201M | XXX | XXX | XXX |
| Net Margin | 8% | XXX | 9% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Carl Zeiss Meditec's stock price is EUR 58 (or $65).
Carl Zeiss Meditec has current market cap of EUR 5.1B (or $5.7B), and EV of EUR 5.2B (or $5.8B).
See Carl Zeiss Meditec trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.8B | $5.7B | XXX | XXX | XXX | XXX | $2.24 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Carl Zeiss Meditec has market cap of $5.7B and EV of $5.8B.
Carl Zeiss Meditec's trades at 2.5x EV/Revenue multiple, and 13.0x EV/EBITDA.
Equity research analysts estimate Carl Zeiss Meditec's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Carl Zeiss Meditec has a P/E ratio of 30.1x.
See valuation multiples for Carl Zeiss Meditec and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5.7B | XXX | $5.7B | XXX | XXX | XXX |
| EV (current) | $5.8B | XXX | $5.8B | XXX | XXX | XXX |
| EV/Revenue | 2.4x | XXX | 2.5x | XXX | XXX | XXX |
| EV/EBITDA | 13.7x | XXX | 13.0x | XXX | XXX | XXX |
| EV/EBIT | 20.2x | XXX | 26.2x | XXX | XXX | XXX |
| EV/Gross Profit | 4.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | 30.1x | XXX | 29.1x | XXX | XXX | XXX |
| EV/FCF | 43.5x | XXX | 47.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCarl Zeiss Meditec's last 12 month revenue growth is 7%
Carl Zeiss Meditec's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.
Carl Zeiss Meditec's rule of 40 is 30% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Carl Zeiss Meditec's rule of X is 35% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Carl Zeiss Meditec and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 19% | XXX | XXX | XXX |
| EBITDA Growth | 14% | XXX | -8% | XXX | XXX | XXX |
| Rule of 40 | 30% | XXX | 26% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 35% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 22% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 17% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 44% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Carl Zeiss Meditec acquired XXX companies to date.
Last acquisition by Carl Zeiss Meditec was XXXXXXXX, XXXXX XXXXX XXXXXX . Carl Zeiss Meditec acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Carl Zeiss Meditec founded? | Carl Zeiss Meditec was founded in 1977. |
| Where is Carl Zeiss Meditec headquartered? | Carl Zeiss Meditec is headquartered in Germany. |
| How many employees does Carl Zeiss Meditec have? | As of today, Carl Zeiss Meditec has 4.8K+ employees. |
| Is Carl Zeiss Meditec publicy listed? | Yes, Carl Zeiss Meditec is a public company listed on ETR. |
| What is the stock symbol of Carl Zeiss Meditec? | Carl Zeiss Meditec trades under AFX ticker. |
| When did Carl Zeiss Meditec go public? | Carl Zeiss Meditec went public in 2000. |
| Who are competitors of Carl Zeiss Meditec? | Similar companies to Carl Zeiss Meditec include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Carl Zeiss Meditec? | Carl Zeiss Meditec's current market cap is $5.7B |
| What is the current revenue of Carl Zeiss Meditec? | Carl Zeiss Meditec's last 12 months revenue is $2.4B. |
| What is the current revenue growth of Carl Zeiss Meditec? | Carl Zeiss Meditec revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Carl Zeiss Meditec? | Current revenue multiple of Carl Zeiss Meditec is 2.4x. |
| Is Carl Zeiss Meditec profitable? | Yes, Carl Zeiss Meditec is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Carl Zeiss Meditec? | Carl Zeiss Meditec's last 12 months EBITDA is $424M. |
| What is Carl Zeiss Meditec's EBITDA margin? | Carl Zeiss Meditec's last 12 months EBITDA margin is 17%. |
| What is the current EV/EBITDA multiple of Carl Zeiss Meditec? | Current EBITDA multiple of Carl Zeiss Meditec is 13.7x. |
| What is the current FCF of Carl Zeiss Meditec? | Carl Zeiss Meditec's last 12 months FCF is $134M. |
| What is Carl Zeiss Meditec's FCF margin? | Carl Zeiss Meditec's last 12 months FCF margin is 6%. |
| What is the current EV/FCF multiple of Carl Zeiss Meditec? | Current FCF multiple of Carl Zeiss Meditec is 43.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
